ArticleDrug design, development and therapy2025
Mechanisms of Total Glucosides of Paeony in Alleviating Methotrexate-Induced Liver Injury.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The correlation between characteristics and pharmacological effects of monoterpene glycosides and tannins in Radix Paeoniae Alba.Journal of pharmaceutical analysis · 2026Review
- Network Pharmacology-Metabolomics Integration Reveals the Multiple Targets and Mechanisms of Total Glucosides of Paeony Against Ulcerative Colitis.Journal of inflammation research · 2026Article
- Identification and Experimental Validation of Key Biomarkers for Rheumatoid Arthritis Based on Bioinformatics Analysis and Machine Learning.Journal of inflammation research · 2026Article
- Mechanistic Exploration of Shenling Baizhu Powder in Treating Irinotecan-Associated Diarrhea: A Study Based on Network Pharmacology and Experimental Validation.Journal of inflammation research · 2025Article
- Research Trends and Hotspots in JAK Inhibitors for Ulcerative Colitis: A Bibliometric Analysis From 2015 to 2024.Journal of multidisciplinary healthcare · 2025Article
- Rheumatoid Arthritis and Fibromyalgia Syndrome: A Bibliometric and Bioinformatics Perspective on Comorbidity Research.Journal of multidisciplinary healthcare · 2025Article
- Knowledge Domain and Emerging Trends in Heart Failure and Anxiety Comorbidity: A Scientometric Analysis.Journal of multidisciplinary healthcare · 2025Article
- Integrating Bibliometrics and Bioinformatics to Map Knowledge Structure and Trend Synthesis in Rheumatoid Arthritis and Bone Erosion (2015-2024).Journal of multidisciplinary healthcare · 2025Article
- Single-Cell Transcriptomics Reveals CCL3Journal of inflammation research · 2025Article
- Integrating Bibliometrics and Bioinformatics to Map Knowledge Structure, Trends, and Genetic Insights in Polycystic Ovary Syndrome and Tumors (2015-2024).Journal of multidisciplinary healthcare · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Total glycoside of peony (TGP) enhances methotrexate efficacy and attenuates its hepatotoxicity in rheumatoid arthritis, but the mechanisms remain unclear. This study investigates the mechanisms of TGP against methotrexate-induced liver injury through a network pharmacology-based approach. Methods: A liver injury model was established in CD-1 mice by intraperitoneal injection of 20 mg/kg methotrexate. TGP and the positive control drug silybin were used to intervene in the methotrexate-induced liver injury model in mice. Serum ALT and AST activities, liver index test and histopathology was detected to evaluate the effects of the treatment on methotrexate-induced liver injury. Additionally, network pharmacology and serum metabolomics were employed to predict the mechanisms of TGP in treating methotrexate-induced liver injury. Experimental validation was conducted by RT-PCR, ELISA and Western blot. Results: TGP effectively alleviated the liver index and pathological liver damage induced by methotrexate and reduced the liver injury markers, serum ALT and AST, showing effects comparable to those of the positive control drug silybin. Network pharmacology predicted that the key targets and key signaling pathways of TGP in treating methotrexate-induced liver injury are closely associated with inflammatory response. Furthermore, serum metabolomics and network pharmacology analysis indicated a close association between effects of TGP on methotrexate-induced liver injury and arachidonic acid pathway. Experimental validation results confirmed that the expression levels of IL-6, TNF and COX-2 in liver tissues were significantly elevated, with the activation of the PI3K/AKT, MAPK, and NFκB pathways. TGP intervention can reverse these changes to a certain extent. Conclusion: TGP treatment effectively mitigates methotrexate-induced liver injury, and its mechanism is closely associated with the inhibition of hepatic inflammatory responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.